Lonza’s board of directors has approved the appointment of Daniel Palmacci as president of its Cell & Gene Division, effective November 1, 2022.   Palmacci takes over the role from Jean-Christophe Hyvert, who continues to serve as president of Lonza’s Biologics Division. Palmacci joins Lonza Group with more than two decades of experience in the pharmaceutical industry, including senior positions at Novartis and Bayer Healthcare. He also brings a wealth of international experience, havi...